Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 16, 2023 - Issue
Submit an article Journal homepage
274
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Low Expression of CLEC2B Indicates Poor Prognosis in Melanoma

Yanqiu ZhangDepartment of Dermatology, The First Hospital of China Medical University, Shenyang, 110001, People’s Republic of ChinaView further author information
,
Yaling LiDepartment of Dermatology, The First Hospital of China Medical University, Shenyang, 110001, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-9136-4990View further author information
ORCID Icon &
Hongwei YanDepartment of Dermatology, The First Hospital of China Medical University, Shenyang, 110001, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 463-477 | Received 18 Nov 2022, Accepted 11 Feb 2023, Published online: 21 Feb 2023

References

  • O’Neill CH, Scoggins CR. Melanoma. J Surg Oncol. 2019;120:873–881. doi:10.1002/jso.25604
  • Bobos M. Histopathologic classification and prognostic factors of melanoma: a 2021 update. Ital J Dermatol Venerol. 2021;156:300–321. doi:10.23736/S2784-8671.21.06958-3
  • Curti BD, Faries MB. Recent advances in the treatment of melanoma. N Engl J Med. 2021;384:2229–2240. doi:10.1056/NEJMra2034861
  • Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019;20:1366–1379. doi:10.1080/15384047.2019.1640032
  • Gao Y, Li Y, Niu X, et al. Identification and validation of prognostically relevant gene signature in melanoma. Biomed Res Int. 2020;2020:5323614. doi:10.1155/2020/5323614
  • Tang S, Huang X, Jiang H, Qin S. Identification of a five-gene prognostic signature related to B cells infiltration in pancreatic adenocarcinoma. Int J Gen Med. 2021;14:5051–5068. doi:10.2147/IJGM.S324432
  • Suzuki-Inoue K. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin. Blood. 2019;134:1912–1918. doi:10.1182/blood.2019001388
  • Guo C, Tang Y, Zhang Y, Li G. Mining TCGA data for key biomarkers related to immune microenvironment in endometrial cancer by immune score and weighted correlation network analysis. Front Mol Biosci. 2021;8:645388. doi:10.3389/fmolb.2021.645388
  • Li Y, Gao Y, Niu X, et al. LncRNA BASP1-AS1 interacts with YBX1 to regulate notch transcription and drives the malignancy of melanoma. Cancer Sci. 2021;112:4526–4542. doi:10.1111/cas.15140
  • Li YL, Gao YL, Niu XL, et al. Identification of subtype-specific metastasis-related genetic signatures in sarcoma. Front Oncol. 2020;10:544956. doi:10.3389/fonc.2020.544956
  • Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014;28:1005–1011.
  • Teixido C, Castillo P, Martinez-Vila C, Arance A, Alos L. Molecular markers and targets in melanoma. Cells. 2021;10. doi:10.3390/cells11010010
  • Lissitzky JC, Parriaux D, Ristorcelli E, Vérine A, Lombardo D, Verrando P. Cyclic AMP signaling as a mediator of vasculogenic mimicry in aggressive human melanoma cells in vitro. Cancer Res. 2009;69:802–809. doi:10.1158/0008-5472.CAN-08-2391
  • Raymond JH, Aktary Z, Larue L, Delmas V. Targeting GPCRs and their signaling as a therapeutic option in melanoma. Cancers. 2022;14(3):706. doi:10.3390/cancers14030706
  • Hong JT, Son DJ, Lee CK, Yoon DY, Lee DH, Park MH. Interleukin 32, inflammation and cancer. Pharmacol Ther. 2017;174:127–137. doi:10.1016/j.pharmthera.2017.02.025
  • Majidpoor J, Mortezaee K. Interleukin-2 therapy of cancer-clinical perspectives. Int Immunopharmacol. 2021;98:107836. doi:10.1016/j.intimp.2021.107836
  • Kirkwood JM, Tarhini AA, Panelli MC, et al. Next generation of immunotherapy for melanoma. J Clin Oncol. 2008;26:3445–3455. doi:10.1200/JCO.2007.14.6423
  • Fridman WH, Petitprez F, Meylan M, et al. B cells and cancer: to B or not to B. J Exp Med. 2021;218. doi:10.1084/jem.20200851
  • Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17:887–904. doi:10.1038/nrd.2018.169
  • Shaul ME, Fridlender ZG. Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol. 2019;16:601–620. doi:10.1038/s41571-019-0222-4
  • Xiong S, Dong L, Cheng L. Neutrophils in cancer carcinogenesis and metastasis. J Hematol Oncol. 2021;14:173. doi:10.1186/s13045-021-01187-y
  • Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16:356–371. doi:10.1038/s41571-019-0175-7
  • Basu A, Ramamoorthi G, Albert G, et al. Differentiation and regulation of T(H) cells: a balancing act for cancer immunotherapy. Front Immunol. 2021;12:669474. doi:10.3389/fimmu.2021.669474
  • Simon S, Utikal J, Umansky V. Opposing roles of eosinophils in cancer. Cancer Immunol Immunother. 2019;68:823–833. doi:10.1007/s00262-018-2255-4
  • Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19:200–218. doi:10.1038/s41573-019-0052-1
  • Knochelmann HM, Dwyer CJ, Bailey SR, et al. When worlds collide: th17 and treg cells in cancer and autoimmunity. Cell Mol Immunol. 2018;15:458–469. doi:10.1038/s41423-018-0004-4

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.